← Back to Screener
Solid Biosciences Inc. Common Stock (SLDB)
Price$8.49
Favorite Metrics
Price vs S&P 500 (26W)36.05%
Price vs S&P 500 (4W)13.27%
Market Capitalization$835.34M
All Metrics
Book Value / Share (Quarterly)$2.28
P/TBV (Annual)0.27x
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-1.99
Price vs S&P 500 (YTD)48.88%
Net Profit Margin (TTM)-588.30%
EPS (TTM)$-2.02
10-Day Avg Trading Volume1.01M
EPS Excl Extra (TTM)$-2.02
EPS (Annual)$-3.05
ROI (Annual)-90.27%
Net Profit Margin (5Y Avg)-2019.34%
Cash / Share (Quarterly)$2.38
ROA (Last FY)-66.26%
EBITD / Share (TTM)$-2.02
ROE (5Y Avg)-61.82%
Operating Margin (TTM)-591.14%
Cash Flow / Share (Annual)$-1.99
P/B Ratio4.64x
P/B Ratio (Quarterly)2.44x
Net Income / Employee (Annual)$-1
EV / Revenue (TTM)52.43x
Net Interest Coverage (TTM)-65.60x
ROA (TTM)-60.18%
EPS Incl Extra (Annual)$-3.05
Current Ratio (Annual)6.14x
Quick Ratio (Quarterly)5.65x
3-Month Avg Trading Volume1.22M
52-Week Price Return242.46%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$7.20
P/S Ratio (Annual)103.26x
Asset Turnover (Annual)0.03x
52-Week High$8.87
Operating Margin (5Y Avg)-2044.22%
EPS Excl Extra (Annual)$-3.05
CapEx CAGR (5Y)5.08%
Tangible BV CAGR (5Y)26.66%
26-Week Price Return44.80%
Quick Ratio (Annual)5.65x
13-Week Price Return48.54%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)6.14x
Enterprise Value$775.442
Asset Turnover (TTM)0.07x
Book Value / Share Growth (5Y)-37.11%
Revenue / Employee (Annual)$0
Pretax Margin (Annual)-1062.79%
Cash / Share (Annual)$2.38
3-Month Return Std Dev94.62%
Net Income / Employee (TTM)$-2
ROE (Last FY)-91.08%
Net Interest Coverage (Annual)-81.57x
EPS Basic Excl Extra (Annual)$-3.05
Receivables Turnover (TTM)162.00x
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-2.02
Receivables Turnover (Annual)147.16x
ROI (TTM)-73.17%
P/S Ratio (TTM)56.48x
Pretax Margin (5Y Avg)-2019.34%
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$10.82
Price vs S&P 500 (52W)207.37%
Year-to-Date Return53.01%
5-Day Price Return2.86%
EPS Normalized (Annual)$-3.05
ROA (5Y Avg)-48.03%
Net Profit Margin (Annual)-1062.79%
Month-to-Date Return19.86%
Cash Flow / Share (TTM)$-4.97
EBITD / Share (Annual)$-2.99
Operating Margin (Annual)-1090.48%
LT Debt / Equity (Annual)0.80x
ROI (5Y Avg)-61.28%
LT Debt / Equity (Quarterly)0.94x
EPS Basic Excl Extra (TTM)$-2.02
P/TBV (Quarterly)0.39x
P/B Ratio (Annual)2.44x
Pretax Margin (TTM)-588.30%
Book Value / Share (Annual)$2.28
Price vs S&P 500 (13W)45.67%
Beta2.63x
Revenue / Share (TTM)$0.00
ROE (TTM)-73.35%
52-Week Low$2.41
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.30
4.32
4.32
4.35
Industry Peers — Biological Products(89)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
SLDBSolid Biosciences Inc. Common Stock | 56.48x | — | — | — | $8.49 |
AMGNAmgen Inc | 5.20x | 9.95% | 73.30% | 2.93% | $350.16 |
GILDGilead Sciences Inc | 5.71x | 2.40% | 78.83% | 133.64% | $135.87 |
ARGXargenx SE American Depositary Shares | 12.59x | 89.56% | 150.91% | — | $834.45 |
BNTXBioNTech SE American Depositary Share | 9.06x | -11.81% | 84.21% | — | $105.19 |
BIIBBiogen Inc. Common Stock | 2.72x | 2.22% | 75.69% | -18.77% | $183.34 |
MRNAModerna, Inc. Common Stock | 10.91x | -39.93% | 70.32% | — | $54.59 |
NBIXNeurocrine Biosciences Inc | 4.64x | 21.45% | 98.18% | 2.31% | $131.59 |
EXELExelixis Inc | 4.89x | 6.85% | 96.39% | 31.10% | $43.61 |
TECHBio-Techne Corp. | 7.72x | 1.64% | 66.60% | -20.58% | $60.58 |
IBRXImmunityBio, Inc. Common Stock | 74.42x | 668.31% | 99.34% | — | $8.20 |
About
Solid Biosciences is a gene therapy company developing treatments for neuromuscular and cardiac diseases, with a primary focus on Duchenne muscular dystrophy (DMD). The company's pipeline includes SB-001 and other programs spanning corrective therapies, disease-modifying therapies, and assistive devices for genetic muscle-wasting conditions.